<DOC>
	<DOCNO>NCT00881582</DOCNO>
	<brief_summary>There distinct lack publish literature effect combination treatment PEG-interferon ribavirin post-renal transplantation hepatitis C virus ( HCV ) patient . Small case series publish utilizing conventional interferon and/or ribavirin available data extremely preliminary nature . A small retrospective series patient treat Pegylated interferon ribavirin publish recently suggest treatment may safe efficacious . Unpublished report center within Saudi Arabia also suggest good safety profile reasonable efficacy form combination treatment . The investigator aim prospectively study safety efficacy PEG-interferon ribavirin combination therapy post-renal transplant HCV-infected patient . Towards 40 patient histological evidence liver disease recruit efficacy medication study . The propose study aim evaluate efficacy safety PEG-interferon ribavirin combination therapy treatment chronic HCV renal transplant patient way allow management patient optimized manner .</brief_summary>
	<brief_title>Peginterferon Alfa-2a Plus Ribavirin Combination Treatment Chronic Hepatitis C Post-Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patients , male female , age 18 68 year Post renal transplant patient exceed one year AntiHCV ( Abbott HCV EIA 2.0 , Abbott Diagnostic , Chicago , IL ) positive &gt; 6 month AND/OR Detectable serum quantitative HCVRNA ( Cobas Amplicor HCV Monitor v2.0 , Roche Molecular Systems , Pleasanton , CA ) low limit detection 50 IU/mL Compensated liver disease follow minimum hematologic biochemical criterion : Hemoglobin &gt; 10 g/dL WBC &gt; 3000/mm3 ; granulocyte count &gt; 1,500/mm3 Platelet count &gt; 75,000/mm3 Albumin within normal limit TFT within normal limit ANA &lt; 1:320 Ultrasound liver obtain within precede 6 month study entry Liver biopsy prior entry confirm histological diagnosis consistent HCV necroinflammatory score ( METAVIR ) &gt; 1 , fibrosis score &gt; /= 2 . Previous treatment interferon / Ribavirin base therapy chronic hepatitis C Coinfection HBV HIV Chronic alcohol abuse ( daily consumption &gt; 20 g/day ) Autoimmune metabolic liver disease liver disease Active druginduced hepatitis HAV Decompensated liver disease ( ChildPugh classification B C ) include past history decompensation Variceal bleed Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) clinically relevant ophthalmological disorder due diabetes mellitis hypertension Neoplastic disease Patients value alphafetoprotein &gt; 100 ng/mL exclude study image study confirm absence HCC . Presence HCC , determine mean also exclude patient histological sampling . Patients document presumed coronary artery disease cerebrovascular disease enrol , judgment investigator , acute decrease hemoglobin 4 g/dL ( 40 g/L ) ( may see ribavirin therapy ) would welltolerated History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease Evidence drug abuse ( include excessive alcohol consumption ) within one year study entry Current pregnancy , ongoing breast feed unwilling contraception Bleeding clotting diatheses Recent history renal allograft rejection ( &lt; 6 month ) Inability unwillingness provide inform consent abide requirement study . History evidence severe illness condition would make patient , opinion investigator , unsuitable study . History organ transplantation , kidney , exist functional graft . Patients require dialysis dialysis impending .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Hepatitis c</keyword>
	<keyword>Renal transplantation</keyword>
	<keyword>Pegylated interferon</keyword>
</DOC>